Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Patients hospitalized in ICU with sepsis (infection with life-threatening organ dysfunction
according to sepsis 3.0 definitions) presumably due to MDR-GNB (multidrug resistant
Gram-negative bacteria). The study will be a prospective multicentre, randomized, open-label
comparative continuous vs. intermittent pivotal βL (Beta Lactamine) antibiotic infusion
strategies and combination vs. monotherapy trial conducted with a 2X2 factorial design.